GLP‑1 drugs like Ozempic show promise for more than weight loss, but what's science vs. hype?
You've probably heard of Ozempic or Wegovy. These are the injectable drugs that have become household names for weight loss and diabetes.
Jun 2, 2026
0
6
Amino Acid, Peptide, or Protein: Semaglutide
Medical news and research articles
How digital platforms and policy shifts reshape GLP-1 affordability
A News and Perspectives report on emerging pharmaceutical access models in the United States has been published in the Journal of Medical Internet Research. In "Affordable GLP-1? When Digital Platforms Meet Policy Reform", ...
Jun 1, 2026
0
4
Global rules could cut costs and speed access to GLP-1 drugs
FDA-approved carbon copies of brand-name drugs with expired patents—over the last 30 years, these generic drugs have saved trillions of dollars for hundreds of millions of people.
Jun 1, 2026
0
6
Weight loss drugs risk widening health inequalities, warn researchers
Drugs such as semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro) are transforming obesity treatment, but without affordable, healthy food and appropriate support, they could widen health inequalities in the UK, according ...
Jun 1, 2026
0
4
EU regulator approves pill form of Novo Nordisk's Wegovy weight loss drug
Novo Nordisk has obtained approval for the pill form of its popular Wegovy anti-obesity drug in the European Union, the bloc's medicines regulator said on Friday.
May 22, 2026
0
9
Weight loss drug semaglutide helps patients who do not respond to bariatric surgery, research finds
Metabolic/bariatric surgery is a highly effective treatment for people living with severe obesity and/or metabolic health conditions, which works through changing the anatomy of the digestive system and thereby changing the ...
May 22, 2026
0
7
Researchers identify avenue for enhanced GLP-1-induced weight loss
A team of researchers at the National Institutes of Health (NIH) have unveiled new details about the events GLP-1 receptor agonists trigger within neurons, which have been largely unexplored until now. A study in mice identified ...
May 22, 2026
0
15
Oral GLP-1s without fasting or reduced efficacy: Delivery approach protects peptide-based drugs from stomach acid
Biomedical engineers at Duke University have developed a new approach to delivering GLP-1 medications orally that does not require fasting and maintains their efficacy. The technique could also be useful for any pharmaceutical ...
May 19, 2026
0
8
Wegovy initiation may cut migraine drug use 8% in women after one year
A nationwide study from Denmark presented at the European Congress on Obesity (ECO2026) in Istanbul, Turkey, shows that use of semaglutide (Wegovy) for weight management is associated with a 7% reduction in the use of triptan-class ...
May 15, 2026
0
7
Endoscopic procedure associated with greater short-term weight loss than oral semaglutide, study finds
A comparative study, presented at ESGE Days 2026, has found that endoscopic sleeve gastroplasty (ESG) is associated with significantly greater short-term weight loss than oral semaglutide in adults with obesity.
May 14, 2026
0
4
